Hematopoietic Cell Transplant Co-Morbidity Index (HCT-CI): Ability to Predict Outcomes in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Authors

Neil D. Palmisiano, MD, Thomas Jefferson UniversityFollow
Sameh Gaballa, MD, Thomas Jefferson University HospitalFollow
Onder Alpdogan, Department of Medical Oncology, Thomas Jefferson University; Department of Immunology and Medicine, Memorial Sloan-Kettering Cancer Center; Department of Medicine, Yale University Medical SchoolFollow
Matthew Carabasi, MD, Thomas Jefferson UniversityFollow
Joanne Filicko-O'Hara, MD, Thomas Jefferson UniversityFollow
Margaret Kasner, MD, Thomas Jefferson UniversityFollow
Ubaldo E. Martinez-Outshoorn, MD, Thomas Jefferson UniversityFollow
John L. Wagner, MD, Thomas Jefferson UniversityFollow
Mark Weiss, MD, Thomas Jefferson UniversityFollow
Neal Flomenberg, MD, Thomas Jefferson UniversityFollow
Dolores Grosso, DNP, Thomas Jefferson UniversityFollow

Document Type

Poster

Publication Date

4-2014

Abstract

Introduction

We developed a 2 step approach to HI HSCT in which a fixed dose of allogeneic T cells are infused after reduced intensity (RIC) or myeloablative conditioning (HSCT step 1). After 2-3 days, cyclophosphamide (CY) 60 mg/kg/d x 2 is given to establish bidirectional tolerance. One day after the CY, a CD 34 selected stem cell product is infused (HSCT step 2).

This approach has been associated with a low incidence of non-relapse mortality (NRM) resulting in a significant improvement in overall survival (OS) in patients (pts) undergoing HI HSCT at our institution. This abstract examined the predictability of this tool in pts undergoing the 2 step HI HSCT.

Recommended Citation

Palmisiano, MD, Neil D.; Gaballa, MD, Sameh; Alpdogan, Onder; Carabasi, MD, Matthew; Filicko-O'Hara, MD, Joanne; Kasner, MD, Margaret; Martinez-Outshoorn, MD, Ubaldo E.; Wagner, MD, John L.; Weiss, MD, Mark; Flomenberg, MD, Neal; and Grosso, DNP, Dolores, "Hematopoietic Cell Transplant Co-Morbidity Index (HCT-CI): Ability to Predict Outcomes in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)" (2014). Department of Medical Oncology Faculty Papers. Paper 28.
https://jdc.jefferson.edu/medoncfp/28